Spero Therapeutics, Inc. (NASDAQ:SPRO) saw its stock surge by 240% on May 28 following the company’s announcement of the ...

Although Wang was not able to quantify the current or near-term threat created by bacterial resistance to antibiotics, he ...

Antibiotics are overused by some and out of reach for others - fuelling resistance and leaving deadly gaps in care.

GSK plans to submit to the US Food and Drug Administration (FDA) for regulatory approval of tebipenem HBr by the end of 2025.

Spero Therapeutics and partner GSK are stopping a late-stage trial of an experimental oral drug for complicated urinary tract ...

According to a press statement issued by Spero on May 28, tebipenem HBr may be the first oral carbapenem antibiotic that patients in the U.S. can get, potentially addressing an estimated 2.9 mil ...

GSK and Spero ended a Phase 3 trial early meeting efficacy goals in cUTIs, positioning its treatment as the first oral ...

Spero Therapeutics, Inc. (NASDAQ:SPRO) saw its stock soar by 240% after announcing highly encouraging results from its Phase ...

These mutated diseases defy the power of antibiotics. Are illnesses really mutating so fast that we can’t stay ahead of them?

Roche is moving its novel antibiotic zosurabalpin into phase 3 testing for carbapenem-resistant Acinetobacter baumannii (CRAB), a 'superbug' that is considered an 'urgent threat' by the CDC, in what ...

In a second piece of good news in the development of new antimicrobials this week, GSK has said it will file its oral ...

Company to launch Zaynich in India this fiscal; sees $7 bn market in US and EU and ₹17,000 crore in India; USFDA, EU filings ...